Charles River Laboratories International, Inc. (NYSE: CRL) has announced the resignation of Flavia H. Pease, the corporate executive vice president and chief financial officer (CFO), effective September 29, 2025. In her place, Michael G. Knell, corporate senior vice president and chief accounting officer, has been appointed as the interim CFO until a successor is named. The company has begun a comprehensive search for its next CFO.
The company is reaffirming its 2025 financial guidance for revenue and non-GAAP earnings per share that was previously provided on August 6, 2025. This reaffirmation is supported by the current outlook for third-quarter performance.
The press release also contains non-GAAP financial measures, such as non-GAAP earnings per diluted share, which exclude items like amortization of intangible assets, purchase accounting step-up adjustment on inventory and certain long-term biological assets, and other charges and adjustments related to acquisitions and divestitures. The company defines "organic revenue growth" as reported revenue growth adjusted for foreign currency translation, acquisitions, and divestitures.
In particular, the company's 2025 revenue and non-GAAP earnings per share guidance has been reaffirmed, and Michael G. Knell has been appointed as the interim CFO following the resignation of Flavia H. Pease. Today the company's shares have moved -0.25% to a price of $151.855. For the full picture, make sure to review CHARLES RIVER LABORATORIES INTERNATIONAL, INC.'s 8-K report.
